Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production

Background: Dengue is now a leading cause of morbidity and mortality throughout the tropics. We conducted the first ex vivo study of dengue fever (DF) in African patients infected during the first Gabonese dengue virus 2 (DENV-2) outbreak in 2007, in order to investigate cytokine production, includi...

全面介紹

Saved in:
書目詳細資料
Main Authors: Pierre Becquart, Nadia Wauquier, Dieudonné Nkoghe, Angélique Ndjoyi-Mbiguino, Cindy Padilla, Marc Souris, Eric M. Leroy
其他作者: Centre International de Recherches Medicales de Franceville
格式: Article
出版: 2018
主題:
在線閱讀:https://repository.li.mahidol.ac.th/handle/123456789/29343
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
機構: Mahidol University
實物特徵
總結:Background: Dengue is now a leading cause of morbidity and mortality throughout the tropics. We conducted the first ex vivo study of dengue fever (DF) in African patients infected during the first Gabonese dengue virus 2 (DENV-2) outbreak in 2007, in order to investigate cytokine production, including the antiviral cytokine IFN-α, reported to be a potent inhibitor of DENV replication in vitro.Methods: Levels of 50 cytokines, chemokines and growth factors were measured in plasma from 36 patients with DENV-2 infection, and in uninfected controls, using Luminex multiplex technology. The results were interpreted according to the day of sampling after symptom onset. PBMC from six patients were also studied for T lymphocyte cell surface marker expression by flow cytometry.Results: Acute DENV-2 infection elicited high levels of several pro-inflammatory cytokines (IL-6 and IL-17), chemokines (MIF, RANTES, IP-10 and MCP-1) and growth factors (G-CSF, GM-CSF and VEGF-A). We also observed high levels of IFN-α for the first time in adult DF patients, and CD4+ and CD8+ T cell activation at symptom onset.Conclusion: Acute DENV-2 infection in African patients elicits a strong innate response involving IFN-α production, as well as an adaptive immune response. © 2010 Becquart et al; licensee BioMed Central Ltd.